Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 MAD Study of Dapiglutide in Overweight/Obesity
NCT06000891Phase 1Terminated
- Sponsor
- Zealand Pharma
- Start
- Sep 2023
- Primary completion
- Feb 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity and Overweight comparing ZP7570 with Placebo (2 arms). Primary endpoint: Incidence of treatment emergent adverse events. Started Sep 2023; status: terminated.
02
Drugs
dapiglutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT06000891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06000891.